Jasper Therapeutics, Inc. announced presentations of data from its preclinical and healthy volunteers studies of briquilimab, as well as trial-in-progress presentations from its BEACON and SPOTLIGHT...
Jasper Therapeutics, Inc. (NASDAQ:JSPRW – Get Free Report) was the target of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 3,800 shares, a drop of 19.1% from the April 30th total of 4,700 shares. Based on an average daily trading volume, of 21,900 […]
Jasper Therapeutics, Inc. (NASDAQ:JSPRW – Get Free Report) was the target of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 3,800 shares, a drop of 19.1% from the April 30th total of 4,700 shares. Based on an average daily trading volume, of 21,900 […]
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
Jasper Therapeutics to Present Data on Briquilimab in Mast globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) has been assigned an average recommendation of “Buy” from the nine research firms that are currently covering the stock, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have covered the stock in the last […]
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are covering the company, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in the last year […]